Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Diabetic Macular Edema, DME
- Main trialPhase 2
- “The objective of this study is to assess the safety, efficacy, and tolerability of SNP318 in patients with DME.”In the company’s words, NCT07199777 on ClinicalTrials.gov
Other drugs for Diabetic Macular Edema
Coming up1
- NovPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Nov 2026 | A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients | |
| Phase 1Completed | 29 Nov 2023 | A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026